Intratumoral gene expression of dihydrofolate reductase and folylpoly-c-glutamate synthetase affects the sensitivity to 5-fluorouracil in non-small cell lung cancer
- PMID: 35201464
- PMCID: PMC8777502
- DOI: 10.1007/s12672-021-00413-w
Intratumoral gene expression of dihydrofolate reductase and folylpoly-c-glutamate synthetase affects the sensitivity to 5-fluorouracil in non-small cell lung cancer
Abstract
Background: Various factors related to the sensitivity of non-small cell lung carcinoma (NSCLC) to 5-fluorouracil (5-FU) have been reported, and some of them have been clinically applied. In this single-institutional prospective analysis, the mRNA expression level of five folic acid-associated enzymes was evaluated in surgical specimens of NSCLC. We investigated the correlation between the antitumor effect of 5-FU in NSCLC using an anticancer drug sensitivity test and the gene expression levels of five enzymes.
Materials and methods: Forty patients who underwent surgery for NSCLC were enrolled, and the antitumor effect was measured using an in vitro anticancer drug sensitivity test (histoculture drug response assay) using freshly resected specimens. In the same sample, the mRNA expression levels of five enzymes involved in the sensitivity to 5-FU were measured in the tumor using real-time PCR. The expression levels and the result of the sensitivity test were compared.
Results: No correlation was found between dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), or DPD/OPRT expression and the antitumor effects of 5-FU. On the other hand, a correlation was found between thymidylate synthase (TS), folylpoly-c-glutamate synthetase (FPGS), and dihydrofolate reductase (DHFR) expression and 5-FU sensitivity.
Conclusion: Expression of FPGS and DHFR may be useful for predicting the efficacy of 5-FU-based chemotherapy for NSCLC.
Keywords: Dihydropyrimidine dehydrogenase; Histoculture drug response assay; Orotate phosphoribosyltransferase; Reverse-transcriptase polymerase chain reaction; Thymidylate synthase.
© 2021. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures


Similar articles
-
Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.World J Gastroenterol. 2012 Aug 14;18(30):3955-61. doi: 10.3748/wjg.v18.i30.3955. World J Gastroenterol. 2012. PMID: 22912546 Free PMC article.
-
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.Int J Mol Med. 2008 Dec;22(6):709-16. Int J Mol Med. 2008. PMID: 19020767
-
Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.Anticancer Res. 2007 Mar-Apr;27(2):851-6. Anticancer Res. 2007. PMID: 17465211
-
Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73. doi: 10.1016/s0925-4439(02)00079-0. Biochim Biophys Acta. 2002. PMID: 12084458 Review.
-
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression.Rare Dis. 2016 Apr 5;4(1):e1165909. doi: 10.1080/21675511.2016.1165909. eCollection 2016. Rare Dis. 2016. PMID: 27274438 Free PMC article. Review.
Cited by
-
Identification of 3-[(4-Acetylphenyl)(4-Phenylthiazol-2-Yl)Amino]Propanoic Acid Derivatives as Promising Scaffolds for the Development of Novel Anticancer Candidates Targeting SIRT2 and EGFR.Pharmaceuticals (Basel). 2025 May 16;18(5):733. doi: 10.3390/ph18050733. Pharmaceuticals (Basel). 2025. PMID: 40430551 Free PMC article.
References
-
- Yoshioka H, Okamoto I, Morita S, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol. 2013;24(5):1326–1331. doi: 10.1093/annonc/mds629. - DOI - PubMed
-
- Ichikawa W, Uetake H, Shirota Y, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 2003;89:1486–1492. doi: 10.1038/sj.bjc.6601335. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources